007 3 1 2003 E

PTO/SB/30 (10-2000)
Approved for use through 10/31/2002. OMB 0651-6631
Patent and Trademark Office; -U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of in infinition unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective May 29, 2000 provides for continued examination of a utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Complete if Known				
Application Number	09/741,680			
Filing Date	December 15, 2000			
First Named Inventor	Vipin Samar			
Group/Art Unit	2171			
Examiner Name	Nguyen, Cam Linh T.			
Attorney Docket Number	OR00-14001			

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 for the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of an RCE to be eligible for the patent term adjustment provisions of the AIPA. See, Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Re. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submissio	n Required under 37 C.F.R. § 1.114							
a. 🛛 Pro	eviously submitted							
 Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on <u>September 26, 2003</u> (Any unentered amendment(s) referred to above will be entered). 								
ii.	ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on							
iii.	Other:	11/03/2003 BABRAHA1 00000041 09741680						
b.		•	01 FC:1801	770.00 OP				
i.	☐ Amendment/Reply		AT LC:10AT					
ii.	☐ Affidavit(s)/Declaration(s)							
iii.	☐ Information Disclosure Statement (IDS)							
iv.	iv. Other: PETITION FOR EXTENSION OF TIME UNDER 37 CFR § 1.136(a)							
2. Miscellan	eous							
	spension of action on the above-identified application is region of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i		7 C.F.R. § 1.103(c)	for a period of	months.			
b. 🔲 Ot	ner:							
3. Fees (The	RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.	R. § 1.114 wh	en the RCE is filed)				
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-1003 (Docket No. OR00-14001) RECEIVED								
i. RCE fee required under 37 C.F.R. § 1.17(e)								
ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)			NOV 0 3 2003					
iii.	Other: Please deduct any underpayments from Depos	sit Account Ni	<u>umber 50-1003.</u>	Tachaology	Contar 2100			
b. A Check in the amount of \$ 770.00, enclosed.				Technology Center 2100				
c. 🔲 Pa	yment by credit card (Form PTO-2038 enclosed).							
	SIGNATURE OF APPLICATION,	ATTORNEY	OR AGENT REC	DUIRED				
Name (Print/Type	Fdward I Grundler Reg	istration No.	47,615	Telephone	530-759-1663			
Signature	Eduf Kelander	-1.	· · · · · · · · · · · · · · · · · · ·	Date	\$4988 R 18,2003			
	CERTIFICATE OF MAI	ILING OR T	RANSMISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent And Trademark Office on:								
Name (Print/Type				and Huddinak O				
Signature	ature Tange Parla				1/28/07			
urden Hour Stat	ement: This form is estimated to take 0.2 hours to complete. T	ime will vary d	epending upon the ne	eds of the individua	case. Any comments on the			

amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.